{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:32:39Z","timestamp":1785148359736,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This article reports a case of a 72-year-old male with intrahepatic cholangiocarcinoma who developed acute symptoms\u2014including chest tightness, muscle weakness, ophthalmoplegia, and dyspnea\u20143 days after receiving the second cycle of adebrelimab, following combination therapy with adebrelimab, apatinib, and tegafur. These complications proved fatal. Laboratory tests showed significant elevation of myocardial injury markers (high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, myoglobin, and creatine kinase). Electrocardiogram showed multi-lead ST-T changes and conduction abnormalities, and neurological examination showed ophthalmoplegia. Immune checkpoint inhibitor-associated myocarditis with myositis\/myasthenia gravis overlap syndrome (IM3OS) was highly suspected. Despite immediate drug discontinuation and progressive immunosuppression with corticosteroids and intravenous immune globulin, the patient\u2019s condition worsened, and cardiac arrest occurred on day 9. This case underscores the rapid onset and poor prognosis associated with adebrelimab-induced suspected IM3OS, highlighting the critical need for rigorous baseline assessment, prompt recognition, early initiation of aggressive immunosuppressive therapy, and coordinated multidisciplinary management to prevent or mitigate these potentially life-threatening immune-related adverse events.<\/jats:p>","DOI":"10.3389\/fonc.2026.1778682","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:55:26Z","timestamp":1781870126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Adebrelimab-associated suspected immune-related myocarditis with myositis\/myasthenia gravis overlap syndrome (IM3OS): A rapidly fatal case and clinical implications"],"prefix":"10.3389","volume":"16","author":[{"given":"Hongyan","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qie","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanbo","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, The Affiliated Hospital of Qingdao University","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3969\/j.issn.1000-8179.2020.20.148","article-title":"Chinese expert consensus on the surveillance and management of immune checkpoint inhibitor-related myocarditis (2020 version)","volume":"47","year":"2020","journal-title":"Chin J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13956","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145186","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","volume":"131","author":"Moslehi","year":"2021","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13540-z","article-title":"Neurological immune-related adverse events of immune checkpoint inhibitors: clinical and hematological risk factors","volume":"273","author":"Marsili","year":"2025","journal-title":"J Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1468569","article-title":"Progress of research on PD-L1 inhibitor adebrelimab usage in Malignant tumors","volume":"14","author":"Cheng","year":"2024","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100317","article-title":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","volume":"6","author":"Jordan","year":"2021","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1253\/circj.CJ-22-0696","article-title":"JCS 2023 Guideline on the diagnosis and treatment of myocarditis","volume":"87","author":"Nagai","year":"2023","journal-title":"Circ J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.103182","article-title":"TACE with doxorubicin-induced cardiotoxicity","volume":"30","author":"Doyon","year":"2025","journal-title":"JACC Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.03.004","article-title":"Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history","volume":"49","author":"Kelly","year":"2013","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004417","article-title":"Cardiotoxicity induced by capecitabine and oxaliplatin in gastric cancer treatment: a rare case of cardiac arrest and cardiogenic shock","volume":"11","author":"Gondal","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"B16","article-title":"The use of the WHO-UMC system for standardised case causality assessment","volume-title":"Uppsala Monitoring Centre","year":""},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03521-w","article-title":"Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials","volume":"147","author":"Hou","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.IJC_1368_20","article-title":"Efficacy and safety of apatinib for elderly patients with previously treated extensive-stage colorectal cancer patients and the prognostic significance of common adverse reactions","volume":"61","author":"Yu","year":"2024","journal-title":"Indian J Cancer"},{"key":"B19","article-title":"Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice","volume":"34","author":"Papanastasopoulos","year":"2014","journal-title":"Anticancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"CIRCULATION"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.hrcr.2019.06.006","article-title":"Immune checkpoint inhibitor-mediated myocarditis and ventricular tachycardia storm","volume":"5","author":"McDowall","year":"2019","journal-title":"HeartRhythm Case Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000023891.80661.ad","article-title":"Successful cardiopulmonary resuscitation after cardiac arrest as a \"sepsis-like\" syndrome","volume":"106","author":"Adrie","year":"2002","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrcardio.2011.38","article-title":"Innate immune signaling in cardiac ischemia","volume":"8","author":"Arslan","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001777","article-title":"Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review","volume":"28","author":"Ghosh","year":"2022","journal-title":"J Clin Rheumatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778682\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:55:39Z","timestamp":1781870139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1778682\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1778682"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1778682","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1778682"}}